Our guest speaker for this session is Brian Culley, who joined Lineage Cell Therapeutics as CEO in September 2018. His broad experience includes the clinical development of pharmaceutical products from research through Phase 3, corporate partnering, institutional capital raising, and numerous other activities.
Lineage Cell Therapeutics Inc is a biotechnology company developing three clinical-stage cell therapy programs based on allogeneic (“off-the-shelf”) cell lines and supported by one of the largest patent estates in cell therapy.
Their lead program is called OpRegen®. OpRegen is in Phase 1/2a clinical development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world.
